# Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.

Study · id `cardio:ct-nct03454724` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03454724](<https://clinicaltrials.gov/study/NCT03454724>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03454724

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 484 participants.

## Technical summary

Registry record NCT03454724. Randomized; no masking; primary purpose treatment. Start 2020-01-01 (anticipated); primary completion 2020-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 484 participants (planned count; ClinicalTrials.gov record NCT03454724, source copy `cardio:ctgov-nct03454724-2019-08-14`, retrieved 2026-10-26)
- Planned start: 2020-01-01 (anticipated) (ClinicalTrials.gov record NCT03454724, source copy `cardio:ctgov-nct03454724-2019-08-14`, retrieved 2026-10-26)
- Primary completion: 2020-12-01 (anticipated) (ClinicalTrials.gov record NCT03454724, source copy `cardio:ctgov-nct03454724-2019-08-14`, retrieved 2026-10-26)
- Completion: 2024-12-01 (anticipated) (ClinicalTrials.gov record NCT03454724, source copy `cardio:ctgov-nct03454724-2019-08-14`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03454724-2019-08-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.
- Acronym: MeReS100-China
- Condition: Coronary Artery Disease
- Intervention (Device): MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System
- Intervention (Device): Xience EES Everolimus Eluting Coronary Stent System
- Lead sponsor: Meril Life Sciences Pvt. Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Meril Life Sciences Pvt. Ltd. (`cardio:org-meril-life-sciences-pvt-ltd`)

## Provenance

Content hash: 57d37e1c9630f7b031f7856e61b3716a28287f4d251a36fd143adc73d1a2e903
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
